
    
      This protocol summary has been updated following Protocol Amendment 4 changes to study
      objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022
      (NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy
      (HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)
      separately.
    
  